Biotech Values

[Mpower]

Clearly your memory and/or your basket of small-cap biotech is selective to your own "theory" .... and your recalcitrance about my being "dismissive" is quite ironic (since you qualify the examples i gave as "exceptions" ... have you considered that maybe JAZZ or the other examples you cited are the exception ... or have you considered that maybe the world is not black and white and you shouldn't generalize so much about everything)

FACTS:

1) On March 20th, 2007, Alexion Pharma (ALXN) received FDA approval for the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, disabling and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis.

- It ran to 22 $'s per share that month (March 07) on news of the approval (from a low of $17).

- It ran to 25 $ by May 07

- It ran to 30 $ by August 07

- It ran to 40 $ by October 07

2) Lev Pharmaceuticals was bought out by Viropharma 3 months after receiving FDA approval for Cinryze, for treatment of both acute and prophylactic hereditary angioedema (HAE), also known as C1 inhibitor deficiency. The company was purchased by Viropharma at a 30% premium over levels traded post FDA approval for Cinryze.